Ponatinib as Initial Therapy in CML-CP


Ponatinib as Initial Therapy in CML-CP
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/24/14)
Cortes JE et al. Ponatinib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP). Proc ASH 2013;Abstract 1483.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.